Benzinga | Aug 26, 2020 09:07AM EDT

Natera's Signatera Test Receives CE Mark

SAN CARLOS, Calif., Aug. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has received the CE mark for the Signatera test, a personalized, tumor-informed ctDNA assay optimized for molecular residual disease (MRD) assessment and treatment monitoring in patients previously diagnosed with cancer. With the CE mark, Natera can now make Signatera available to clinics and hospital systems throughout Europe to support patient management and clinical research.